Posted by Michael Wonder on 16 Dec 2022
CSL receives positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with haemophilia B
16 December 2022 - Regulatory milestone moves CSL one step closer to bringing the promise of gene therapy for haemophilia B to patients in Europe.
CSL today announced that the EMA's CHMP has adopted a positive opinion recommending conditional marketing authorisation of etranacogene dezaparvovec.
